

Enrolling Studies

Hepatitis C

GS-US-256-0148: Phase 2B

To evaluate the antiviral efficacy as measured by SVR of response guided therapy (RGT) with GS-5885(DAA) +GS-9451(Protease) + PEG/RBV or GS-5885 + PEG/RBV in **treatment naïve subjects with GT 1 chronic HCV**

Treatment	2:1
1	RGT with GS-5885 30mg QD + GS-9451 200mg + PEG/RBV
3	RGT with GS-5885 30mg QD +GS-9451 placebo QD + PEG/RBV

Duration of therapy is based on patient response and randomization. There is the potential to stop therapy at week 12, 24, or 48

Key Inclusion:

- Male or female 18-70 with Chronic hepatitis C, Genotype 1
- HCV RNA > 10,000 IU/mL at screening;
- Liver biopsy within 2 years; with no evidence of Cirrhosis

Key Exclusion:

- No prior HCV treatment

Enrolling Studies

Hepatitis C

GS-US-248-131: Phase 2

To evaluate the antiviral efficacy as measured by SVR of combination therapy with GS-5885(DAA), GS-9451 (Protease), tegobuvir (polymerase) and RBV compared with GS-5885, GS-9451 and tegobuvir or GS-5885, GS-9451 and RBV in **GT 1a or 1b treatment experienced** (non-responder, relapse, or breakthrough) subjects

Treatment	1:1:1
1	GS-5885 90mg QD + GS-9451 200mg QD + tegobuvir 30mg BID + RBV BID
2	GS-5885 90mg QD + GS-9451 200mg QD + tegobuvir 30mg BID + RBV placebo BID
3	GS-5885 90mg QD + GS-9451 200mg QD + tegobuvir placebo BID + RBV BID

Subjects who achieve vRVR (HCV RNA < LOQ at week 2) will stop therapy at week 24

Key Inclusion:

- Male or female ≥18 years with Chronic hepatitis C, Genotype 1
- HCV RNA > 10,000 IU/mL at screening
- Prior treatment and adherence with PEG and RBV
- Liver biopsy within 3 years; with no evidence of cirrhosis

Key Exclusion:

- No prior treatment of oral HCV antiviral (exclusive of RBV)

Enrolling Studies

Continued from page 1

Hepatitis C

GS-US132: Phase 2

To evaluate the antiviral efficacy as measured by SVR of combination therapy with GS-5885(DAA), GS-9451(Protease), tegobuvir (polymerase) and ribavirin (RBV), or GS-5885, GS-9451 and tegobuvir or GS-5885, GS-9451 and RBV in **Interferon (IFN) ineligible or intolerant subjects**

Treatment	1:1:1
1	GS-5885 90mg QD + GS-9451 200mg QD+ tegobuvir 30mg BID+RBV BID
2	GS-5885 90mg QD +GS-9451 200mg QD+ tegobuvir 30mg BID +RBV placebo BID
3	GS-5885 90mg QD +GS-9451 200mg QD+ tegobuvir placebo BID +RBV BID

Treatment duration is 24 weeks

Key Inclusion:

- Male or female ≥ 18 years with Chronic hepatitis C, Genotype 1a or 1b
- HCV RNA $> 10,000$ IU/mL at screening;
- IFN ineligible defined by: seizure disorder, poorly controlled diabetes or thyroid dysfunction, autoimmune, retinal or psychiatric disease

or

- IFN intolerant defined by: less than 12 weeks of treatment (ending ≥ 6 months prior to screening) with IFN that was stopped due to IFN related AE
- Liver biopsy within prior ≤ 3 years; with no evidence of cirrhosis

Key Exclusion:

- Methadone use is not allowed, stable buprenorphine for ≥ 6 months is permitted

Enrolling Studies

Hepatitis C

AI-444-043: Phase 3

To evaluate the safety and efficacy of BMS-790052(DAA) plus Peg-Interferon Alfa 2a and RBV in previously untreated **HCV patients coinfecting with HIV and HCV**

Treatment	
1	BMS -790052 (30, 60, or 90mg QDay) + PEG/RBV for 24 weeks

Treatment: This is an open label study. Approximately 300 subjects will begin treatment with BMS-790052 plus peg-IFN α -2a/RBV for 24 weeks. The dose of BMS-790052 will be 60 mg QD, unless otherwise dictated by concomitant HAART therapy (30 mg QD with ritonavir and 90 mg QD with NNRTIs).

Subjects will be evaluated for Virologic Response (VR), defined as HCV RNA undetectable at both Weeks 4 and 12. This will be referred to as VR (4 & 12). Treatment will be assigned as follows:

- Subjects who achieve VR (4 & 12) will complete 24 weeks of triple therapy
- Subject not achieving VR (4 & 12) will be required to receive 48 weeks total duration

Key Inclusion:

- Male or female 18-70 years with Chronic hepatitis C, Genotype 1a or 1b
- HCV treatment naive
- **Compensated cirrhosis is permitted**

Key Exclusion:

- Confirmed uncontrolled hypertension (any screening systolic blood pressure ≥ 160 mmHg or diastolic ≥ 100 mmHg)
- Uncontrolled diabetes (screening HgA1c ≥ 8.5)

Enrolling Studies

Continued from page 2

Hepatitis C

TMC435HPC2002: Phase 2a

To evaluate efficacy and safety of 12 weeks or 24 weeks of TMC435 in combination with PSI-7977 with or without ribavirin in chronic hepatitis C genotype 1-infected prior **null responders** to peginterferon/ribavirin therapy

Cohort 1 (Metavir F0/F1/F2)

Treatment	2:1:2:1
1	24 weeks of TMC435 (150 mg q.d.) +PSI-7977 (400 mg q.d.) with RBV
2	24 weeks of TMC435 (150 mg q.d.) plus PSI-7977 (400 mg q.d.)
3	12 weeks of TMC435 (150 mg q.d.) plus PSI-7977 (400 mg q.d.) with RBV
4	12 weeks of TMC435 (150 mg q.d.) plus PSI-7977 (400 mg q.d.)

Enrollment into Cohort 2 (Metavir F3/F4)

An interim analysis will be performed when all subjects in Cohort 1 have reached the SVR12 time point for the purpose of deciding which arms in Cohort 1 will be taken forward into Cohort 2

Key Inclusion:

- Male or female ≥ 18 years with Chronic hepatitis C, Genotype 1
- **Treatment Null responder (<2-log drop after 12 weeks of therapy)**

Key Exclusion:

- Received opioid substitution drugs (methadone, buprenorphine/naloxone) within 6 months before screening
- Cohort 2 specific: AFP > 50 ng/mL.


Enrolling Studies

Hepatitis C


M11-652: Phase 2b

To evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 with Ritonavir (ABT-450/r) in combination with ABT-267 and/or ABT-333 with and without Ribavirin (RBV) for 8, 12 or 24 weeks in Treatment-Naïve and Null Responder Subjects with Genotype 1 Chronic Hepatitis C Virus Infection

Treatment Schematic:



*Cohort 2



Cohort 1 randomization 2:1:1:2:1:1:1:1

Cohort 2 randomization 2 :1:1:1:1

Key Inclusion:

- Male or female ≥ 18 -70 years with Chronic hepatitis C, Genotype 1a or 1b
- **Treatment Naïve or Null responder**

Key Exclusion:

- Cirrhosis
- Uncontrolled diabetes (screening HgA1c > 8.0)